Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01860170 · ClinicalTrials.gov registry record · Phase 1
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
A Phase 1 study, sponsored by Corewell Health West.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01860170: Completed Phase 1 study, sponsored by Corewell Health West.
NCT01860170 is a Phase 1 study that has completed, run by Corewell Health West. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01860170, a Phase 1 study, has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Bortezomib, known commercially as Velcade is safe and tolerated at different dose levels (amounts) with high dose Cyclophosphamide to be used as graft versus host disease prevention after reduced-intensity allogeneic hematopoietic stem cell transplantation.
Primary Outcome
Grade 3 non-hematologic Common Toxicity Criteria toxicity directly related to bortezomib (such as peripheral neuropathy) or Grade 2 or \> hepatic bilirubin Common Toxicity Criteria Graft failure
Interventions
- DRUG Cohort 1-Bortezomib (Velcade ®)
- DRUG Cohort 2-Bortezomib (Velcade ®)
- DRUG Cohort 3-Bortezomib (Velcade ®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-04 |
| Est. Completion | 2018-03 |
| Phase | Phase 1 |
What the finished NCT01860170 record still lists
NCT01860170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 3 interventions - of which Cohort 1-Bortezomib (Velcade ®) is the first listed.
NCT01860170 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01860170 about?
NCT01860170 is a clinical study titled "Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis". The purpose of this study is to determine if Bortezomib, known commercially as Velcade is safe and tolerated at different dose levels (amounts) with high dose Cyclophosphamide to be used as graft versus host disease prevention after reduced-intensity allogeneic hematopoietic stem cell transplantatio...
What is the current status of trial NCT01860170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2012-04. Estimated completion is 2018-03.
What interventions are being tested in trial NCT01860170?
The interventions under investigation include: Cohort 1-Bortezomib (Velcade ®) (DRUG), Cohort 2-Bortezomib (Velcade ®) (DRUG), Cohort 3-Bortezomib (Velcade ®) (DRUG).
Who is sponsoring clinical trial NCT01860170?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01860170's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia